KTE-C19, an Anti-CD19 Chimeric Antigen an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy in Adult Patients (pts) with Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL) in the ZUMA-3 Trial: Preliminary Results of Novel Safety Interventions

Bijal Shah,Wendy Stock,William Wierda,Max Topp,Marie Jose Kersten,Roch Houot,Nicolas Boissel,Houston Holmes,Gary Schiller,Armen Mardiros,John Rossi,Yizhou Jiang,Tong Shen,Jeff Aycock,Shanna Stout,Jeff Wiezorek,Rajul Jain

Clinical lymphoma myeloma & leukemia/Clinical lymphoma, myeloma and leukemia（2017）

引用 1|浏览22

暂无评分

摘要

Outcomes in adult R/R ALL are poor. Promising results were observed with axi-cel (formerly KTE-C19) in B cell malignancies. Severe cytokine release syndrome (CRS) and neurologic events (NE) have been observed with anti-CD19 CAR T cell therapy in R/R ALL.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要